TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00365690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-administered coping improvement therapy
Description: Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-administered supportive-expressive therapy
Description: Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual therapy
Description: Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
Study: NCT04525898

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone
Description: The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
Study: NCT02246296

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard F75 Milk
Description: This is the standard F75 milk used worldwide (Control group)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified F75 Milk
Description: This is the experimental group
Study: NCT03237156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906
Description: TAK-906 capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-906 Placebo
Description: Placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-906 Placebo
Description: Placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-906 Placebo
Description: Placebo capsules.
Study: NCT03105297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype nasal dilator strip
Description: External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype nasal dilator strip
Description: External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype nasal dilator strip
Description: External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No strip
Study: NCT00216060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Daily oral risedronate combined with androgen deprivation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral placebo combined with androgen deprivation
Study: NCT02404558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab
Description: Pharmaceutical form:solution Route of administration: Subcutaneous injection
Study: NCT02581917

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of PBMC samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Undergo metabolic analysis
Study: NCT00860145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiosurgery
Description: The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: temporal lobectomy
Description: The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
Study: NCT01268839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25mg tablet once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25mg tablet once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600mg tablet once daily for 14 days
Study: NCT01386125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray (MFNS)
Description: MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MFNS
Description: Two sprays in each nostril BID for up to 16 weeks
Study: NCT01630616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: single oral dose, tablets, 10 or 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: single oral dose, tablets, 10 or 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odanacatib
Description: single oral dose, tablets, 10 or 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose, tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose, tablets
Study: NCT03359720

Intervention type: OTHER
Intervention: no intervention survey
Description: survey
Study: NCT04125914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Record food intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-mail
Description: Receive e-mails
Study: NCT03359720

Intervention type: OTHER
Intervention: no intervention survey
Description: survey

Intervention type: OTHER
Intervention: no intervention survey
Description: survey
Study: NCT03200145

Intervention type: OTHER
Intervention: ACP intervention
Description: The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~1. - Attention to the person based on:~   * Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~  * Respect and acknowledge of the person.~  * Promotion of the autonomy.~  * Personalized treatment, with tailored attention and integrative cures~  * Protection of physical well-being, preventing damages and risks and promoting healthy habits.~  * Promotion of independence on daily activities.~  * Protection of privacy and personal matters~2. - Positive environment based on:~   * Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~  * Social relationships, with proximity and collaboration with families.~  * Friendly organization, with empathetic professionals empowering users.
Study: NCT01156467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)
Description: Treatment with Edi-catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group, ventilation with i-Servo or Stephanie
Description: Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
Study: NCT02219100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home administration of 200 mg mifepristone
Description: Home administration of 200 mg mifepristone
Study: NCT04824287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle exercise
Description: pelvic floor muscle exercises training from the researcher using the Roy Adaptation Model in addition to routine discharge training Face-to-face training was given to the individuals in the experimental group on the day before the operation, on the second and third postoperative days, and on the day of discharge. The training continued with phone calls at the first, second and third weeks and the first, second, third, and sixth months after the surgery Patients practiced exercises 6 month after surgery
Study: NCT02489487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg Raltegravir
Study: NCT04290312

Intervention type: OTHER
Group type: OTHER
Intervention: Mastiha oil
Description: After overnight fasting, the authorized study staff inserted a plastic cannula in an arm vein of the volunteers in order to minimize discomfort during consecutive blood sampling. A blood sample was collected on time point 0h and then the volunteers consumed 1mL of MO. The dose selection was based on the study of Papada et al. (2017) who administered healthy volunteers with 10g of Mastiha (containing \~10% MO). Afterwards blood samples were collected on time points 0.5h, 1h, 2h, 4h, 6h and 24h after MO intake, and were centrifuged at 3000rpm for 10 minutes at 4◦C for plasma and serum isolation. All samples were stored at -80◦C until further analysis.
Study: NCT00650234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 500 mg
Description: 500mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR Tablets 500 mg
Description: 500mg, single dose fasting
Study: NCT02966041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
Study: NCT04597164

Intervention type: OTHER
Intervention: Artificial liver support system
Description: Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (PE) for three times, and comprehensive internal medical treatment. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in PE is 1000 millilitre.
Study: NCT02497300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Study: NCT01483807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment - Blocked
Description: Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment - Blocked
Description: Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment - Random
Description: A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sound Production Treatment - Random
Description: A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
Study: NCT01960673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA proseal
Description: It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: igel LMA
Description: It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air Q LMA
Description: It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ambu LMA
Description: It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
Study: NCT02819518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT00613730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Intravenous administration
Study: NCT04125914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Join Facebook page
Study: NCT02819518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normale Saline Solution
Description: IV infusion
Study: NCT03793868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral tablet
Study: NCT03254732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
Study: NCT03793868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (not drug)
Study: NCT01580514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide BYETTA® (Amylin-Lilly)
Description: After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.
Study: NCT04125914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01756300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celsius® ThermoCool® RD
Description: The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
Study: NCT03230253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential training
Description: The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual training
Description: The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
Study: NCT04125914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone coaching
Study: NCT03770130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, a kind of crystalloid widely used in clinical treatment